---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-036821"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:25:28.715053+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics raises $30M, confirms partial response for APR-1051 in Phase 1 trial

## Summary
- Raised ~$30M via pre-funded warrants ($0.808) and common warrants ($0.683) expiring Dec. 31, 2029; led by Soleus Capital.
- Confirmed partial response in PPP2R1A-mutated endometrial cancer patient at 220 mg; target lesion reduction 59.5%, CA-125 drop from 362 to 40.2 U/mL.
- Two partial responses in endometrial cancer with PPP2R1A mutations; five stable diseases including HPV+ HNSCC, colorectal, and endometrial cancers.
- Cash runway extended into Q1 2028; dose escalation to 300 mg QD planned in Q2 2026.
- Oversubscribed offering; Oppenheimer & Co. and Maxim Group acted as placement agents.

## SEC filing metadata
- accession: 0001104659-26-036821
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/0001104659-26-036821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/tm2610566d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-036821
- JSON: https://secwatch.observer/filing/0001104659-26-036821.json
- Plain text: https://secwatch.observer/filing/0001104659-26-036821.txt

## Key facts
- Material Agreements
  Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Gross proceeds of approximately $30 million (effective 2026-03-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: Gross proceeds of approximately $30 million
  - Effective: 2026-03-30
  source text: On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to approximately 37.2 million shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.683 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/0001104659-26-036821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.